Summary
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
History
SciClone Pharmaceuticals was founded in 1998 in San Francisco, California by an entrepreneurial group of medical, business, and research professionals. In 2004, the company closed a $50 million financing round to commercialize treatments for cancer, hepatitis C, and other infectious diseases. SciClone went public in 2006 and has since grown to become a pioneer in the development of innovative therapies for treating serious diseases.
Mission
Our mission is to discover and develop therapeutics that empower patients to defeat serious diseases and improve their quality of life.
Vision
At SciClone, we’re driven by our unique culture of innovation, passion, collaboration, and excellence. We want to provide patients with access to safe and effective treatments, while striving to be a leader in the development of cutting-edge therapeutics.
Key Team
Mr. Min Jia (VP & Head of Immunization Bus. Unit)
Mr. Yansong Chang (VP & GM of Oncology Bus. Unit)
Mr. Mingxiang Wu (VP and Head of Market Access & Commercial Operation (MACO) Department)
Dr. Xiaoning Guo (VP, Head of R&D Department and Chief Medical Officer)
Mr. Lianzong Wu (VP and Head of Registration & Pharmaceutical Affairs Department)
Dr. Li Mao (VP, GM of R&D & Chief Medical Officer)
Ms. Sin Man Chan (Joint Company Sec.)
Recognition and Awards
SciClone has been recognized for numerous industry awards, including “Company of the Year” by the BioPharma Awards in 2018, “Best Biotech Company” by the San Francisco Chronicle in 2019, and “Most Innovative Biopharmaceutical” by the American Biotechnology Association in 2020.
References
